Eplerenone inhibits UUO-induced lymphangiogenesis and cardiac fibrosis by attenuating inflammatory injury.

Abstract

Cardiorenal syndrome (CRS) is the leading cause of death associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). However, the underlying mechanisms of CRS are still poorly understood. Here, we studied a CKD model of unilateral ureteral obstruction (UUO) and observed pathological cardiac fibrosis and lymphangiogenesis in 180-day old UUO rats, in which inflammatory injury plays a major role. In addition, treatment of UUO rats with eplerenone, a mineralocorticoid receptor blocker (MRB), significantly reduced cardiac lymphangiogenesis and fibrosis. In conclusion, our experimental results showed that cardiac lymphangiogenesis in long-term UUO rats may be involved in the formation of cardiac fibrosis and that eplerenone can alleviate lymphangiogenesis and cardiac fibrosis by inhibiting inflammation.

• Authors: Gege Chen, Yi Chang, Yunzhao Xiong, Juan Hao, Lingjin Liu, Ziqian Liu, Hui Li, Panpan Qiang, Yutong Han, Yunqian Xian, Tatsuo Shimosawa, Xiangting Wang, Fan Yang, Qingyou Xu
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 108 Pg. 108759 (Jul 2022) ISSN: 1878-1705 [Electronic] Netherlands
• PMID: 35428023 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Elsevier B.V. All rights reserved.

Chemical References

• Eplerenone

Topics

• Animals
• Disease Models, Animal
• Eplerenone (therapeutic use)
• Fibrosis
• Kidney (pathology)
• Lymphangiogenesis
• Rats
• Renal Insufficiency, Chronic (complications)
• Ureteral Obstruction (complications)